Celltaxis Announces Peer-Reviewed Publication of Clinical Data Supporting Its Novel Therapeutic Approach to Lymphedema

Data ReadoutpositiveLTA4H inhibitorPositive

AI Analysis

Summary

Celltaxis announced peer-reviewed publication of clinical data in Scientific Reports showing significant improvements in limb volume, skin thickness, tissue architecture, and quality of life with once-daily oral LTA4H inhibitor treatment for lymphedema.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Clinical data published in Scientific Reports demonstrated significant improvements in limb volume, skin thickness, tissue architecture and quality of life following once-daily oral treatment

Importance:6/10

Sentiment:

0.70

lymphedemaLTA4H inhibitorclinical datapeer-reviewed publicationquality of life

Related Companies

$INTI

Read the original article

Published by PR Newswire Biotech on October 7, 2026 12:33 PM

Read Original